Concepedia

Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing <i>BCR-ABL1</i> <sup>T315I</sup>-compound mutations.

Karoline V. Gleixner, Yüksel Filik, Daniela Berger, Christina Schewzik, Gabriele Stefanzl, Irina Sadovnik, Lina Degenfeld‐Schonburg, Gregor Eisenwort, Mathias Schneeweiss‐Gleixner, Konstantin Byrgazov,

PubMed · 2021 · 41 citations · 27 references

Full text

Open access

Concepts

Abstract

compound mutations and CML stem cells. The clinical efficacy of this TKI combination needs to be evaluated within the frame of upcoming clinical trials.

References

27

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Ting‐Chao Chou, Paul Talalay · Advances in Enzyme Regulation · 1984 · 7.2K citations

, , +16

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

, , +13

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu et al. · Cancer Cell · 2009 · 1.2K citations · Full text

, , +9

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

, , +17

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

Mhairi Copland, Ashley Hamilton, Lucy J. Elrick et al. · Blood · 2006 · 633 citations · Full text

, , +5